Evidence map›Paper›PMID 40766574›Full record

ArticlebioRxiv : the preprint server for biology2025

Pentilludin reduces rat amphetamine and remifentail self-administration with good pharmacologic and toxicologic profiles.

George Uhl, Balaji Kannan, Joungil Choi, Ian Henderson, Bridget Gregory, Jared Solon, Corinne Wells, Edward D Levin

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

George UhlDepartment of Neurology, University of Maryland School of Medicine, Baltimore MD 21201.
Balaji KannanDepartment of Neurology, University of Maryland School of Medicine, Baltimore MD 21201.
Joungil ChoiVA Maryland Healthcare System, Baltimore MD 21201.
Ian HendersonOmphalos Bioscience LLC, Sandia Park NM 87047.
Bridget GregoryDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham NC 27710.
Jared SolonDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham NC 27710.
Corinne WellsDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham NC 27710.
Edward D LevinDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham NC 27710.

Funding

PTPRD ligands for stimulant and opiate use disordersU01DA047713 · NIDA · BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX · PI UHL, GEORGE RICHARD, WESTLUND-HIGH, KARIN N. · 2019 to 2021
$5.0M
PTPRD Phosphatase inhibitors for stimulant use disordersUG3DA056039 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI UHL, GEORGE RICHARD · 2022 to 2024
$3.5M
NIDA NIH HHS U01 DA047713NIDA NIH HHS UG3 DA056039
6 · The paper itself

Abstract

Pentilludin is a novel, potent (690 nM) irreversible inhibitor of actions of the receptor type protein tyrosine phosphatase D (PTPRD). Pentilludin displays no

Identifiers

PMID40766574
PMCPMC12324336

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.